Cardiovascular outcomes with semaglutide by severity of chronic kidney disease in type 2 diabetes: the FLOW trial

赛马鲁肽 医学 2型糖尿病 肾脏疾病 糖尿病 内科学 疾病 心脏病学 重症监护医学 内分泌学 利拉鲁肽
作者
Kenneth W. Mahaffey,Katherine R. Tuttle,Mustafa Arici,Florian M.M. Baeres,George L. Bakris,David M. Charytan,David Z.I. Cherney,Gil Chernin,Ricardo Correa‐Rotter,Janusz Gumprecht,Thomas Idorn,Giuseppe Pugliese,Ida Kirstine Bull Rasmussen,Søren Rasmussen,Peter R Rossing,Ekaterina Sokareva,Johannes F.E. Mann,Vlado Perkovic,Richard E. Pratley
出处
期刊:European Heart Journal [Oxford University Press]
卷期号:46 (12): 1096-1108 被引量:60
标识
DOI:10.1093/eurheartj/ehae613
摘要

BACKGROUND AND AIMS: In the FLOW trial, semaglutide reduced the risks of kidney and cardiovascular (CV) outcomes and death in participants with type 2 diabetes and chronic kidney disease (CKD). These prespecified analyses assessed the effects of semaglutide on CV outcomes and death by CKD severity. METHODS: Participants were randomized to subcutaneous semaglutide 1 mg or placebo weekly. The main outcome was a composite of CV death, non-fatal myocardial infarction (MI), or non-fatal stroke (CV death/MI/stroke) as well as death due to any cause by baseline CKD severity. CKD was categorized by estimated glomerular filtration rate < or ≥60 mL/min/1.73 m2, urine albumin-to-creatinine ratio < or ≥300 mg/g, or Kidney Disease Improving Global Outcomes (KDIGO) risk classification. RESULTS: Three thousand, five hundred and thirty-three participants were randomized with a median follow-up of 3.4 years. Low/moderate KDIGO risk was present in 242 (6.8%), while 878 (24.9%) had high and 2412 (68.3%) had very high KDIGO risk. Semaglutide reduced CV death/MI/stroke by 18% [hazard ratio (HR) 0.82 (95% confidence interval 0.68-0.98); P = .03], with consistency across estimated glomerular filtration rate categories, urine albumin-to-creatinine ratio levels, and KDIGO risk classification (all P-interaction > .13). Death due to any cause was reduced by 20% [HR 0.80 (0.67-0.95); P = .01], with consistency across estimated glomerular filtration rate categories and KDIGO risk class (P-interaction .21 and .23, respectively). The P-interaction treatment effect for death due to any cause by urine albumin-to-creatinine ratio was .01 [<300 mg/g HR 1.17 (0.83-1.65); ≥300 mg/g HR 0.70 (0.57-0.85)]. CONCLUSIONS: Semaglutide significantly reduced the risk of CV death/MI/stroke regardless of baseline CKD severity in participants with type 2 diabetes.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
zhoushishan完成签到,获得积分10
1秒前
还单身的玫瑰完成签到,获得积分10
1秒前
无限的芷云完成签到,获得积分10
1秒前
Geng完成签到,获得积分10
1秒前
1秒前
飞鸿影下完成签到 ,获得积分10
1秒前
初七完成签到 ,获得积分10
2秒前
2秒前
耶耶完成签到,获得积分10
2秒前
田様的应助被感动的莞采纳,获得10
2秒前
2秒前
积极慕晴完成签到,获得积分10
3秒前
泡泡不咕咕完成签到,获得积分10
3秒前
dididi发布了新的文献求助10
3秒前
3秒前
KEFE完成签到,获得积分10
3秒前
yu完成签到,获得积分20
4秒前
SciGPT的应助被研二就毕业采纳,获得10
4秒前
kou完成签到 ,获得积分10
4秒前
4秒前
苗条梦玉完成签到,获得积分10
4秒前
郝南烟发布了新的文献求助30
4秒前
daixan89完成签到 ,获得积分10
5秒前
Jeff发布了新的文献求助10
5秒前
5秒前
稞小弟完成签到,获得积分0
5秒前
5秒前
瘦瘦完成签到,获得积分10
5秒前
兴奋醉香发布了新的文献求助10
5秒前
隔壁老王完成签到,获得积分10
5秒前
缪缪思思发布了新的文献求助10
6秒前
6秒前
你好发布了新的文献求助10
6秒前
6秒前
董涛完成签到,获得积分10
6秒前
6秒前
研友_Zr24bZ发布了新的文献求助10
6秒前
落寞电灯胆完成签到,获得积分10
7秒前
所所的应助被科学家采纳,获得10
7秒前
vcfvc完成签到,获得积分10
7秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1500
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology)求助 1000
Encyclopedia of Modern Artificial Intelligence 1000
John McDowells Bildungstheorie 800
Analyses de reconnaissances de dettes passées devant les échevins d'Ypres (1249-1291) 600
Synthesis, Application and Future Perspectives of Smart Nano-materials - Part 1 400
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8152442
求助须知:如何正确求助?哪些是违规求助? 9549069
关于积分的说明 21690841
捐赠科研通 7740658
什么是DOI,文献DOI怎么找? 3425157
关于科研通互助平台的介绍 2550382
邀请新用户注册赠送积分活动 2468710